Showing results (301-310 of 321) with videos related to
Sort By:
Pageof 33
The American Journal of Cardiology|August 1, 1987
Heterogeneous myocardial catecholamine concentrations in patients with congestive heart failureG L Pierpont, G S Francis, E G DeMaster, et al.American Heart Journal|September 1, 1982
Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placeboJ A Franciosa, K T Weber, T B Levine, et al.Age and Ageing|August 18, 2001
Relationship between periventricular or deep white matter lesions and arterial elasticity indices in very old peopleD A Duprez, M L De Buyzere, N Van den Noortgate, et al.Journal of Molecular and Cellular Cardiology|May 18, 1999
Localization of changes in beta-actin expression in remodeled canine myocardiumB Tian, W C Carlyle, W G Weigold, et al.Circulation|September 15, 1996
Effects of A1 adenosine receptor agonism using N6-cyclohexyl-2'-O-methyladenosine in patients with left ventricular dysfunctionB D Bertolet, I S Anand, R J Bryg, et al.Circulation|December 1, 1994
Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dogK M McDonald, M Garr, P F Carlyle, et al.American Heart Journal|January 1, 1992
A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failureS D Katz, S H Kubo, M Jessup, et al.Circulation|August 5, 1997
Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study GroupJ N Cohn, S Ziesche, R Smith, et al.The New England Journal of Medicine|May 3, 2001
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failureC W Yancy, M B Fowler, W S Colucci, et al.American Journal of Hypertension|March 1, 1991
Reduced vascular compliance as a marker for essential hypertensionG E McVeigh, D E Burns, S M Finkelstein, et al.Pageof 33